Interim report January-September 2009

Third quarter 2009 • Net sales decreased by 2 percent to 90.6 MSEK (92.3). At comparable exchange rates sales decreased by 13 percent. • The operating result amounted to 2.0 MSEK (7.0). • The result after tax amounted to 1.4 MSEK (6.6). • Earnings per share amounted to 0.01 SEK (0.14). • Net cash at September 30, 2009 amounted to 326.6 MSEK. • As a part of Biotage’s buy-back program 158,779 own shares were repurchased at a total value of 1.1 MSEK, i.e. an average share price of 6.93 SEK. • The cash flow from operating activities amounted to 4.5 MSEK (13.0). January - September 2009 • Net sales increased by 7 percent to 294.6 MSEK (276.3). At comparable exchange rates sales decreased by 11 percent. • The operating result amounted to -13.7 MSEK (10.8). Before restructuring costs the operating result amounted to 7.5 MSEK (10.8). • The result after tax amounted to -14.5 MSEK (8.8). • Earnings per share amounted to -0.16 SEK (0.38). • Net cash at September 30, 2009 amounted to 326.6 MSEK. • Dividends to shareholders have been paid to the amount of 17.7 MSEK. • As a part of Biotage’s buy-back program 158,779 own shares were repurchased at a total value of 1.1 MSEK. • The cash flow from operating activities amounted to 21.2 MSEK (10.2).

About Us

Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by public authorities, academic institutions, contract research and contract manufacturing organizations and in the pharmaceutical and food industries, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 390 employees and had sales of 748 MSEK in 2017. Biotage is listed on Nasdaq Stockholm. Website: www.biotage.com

Subscribe

Documents & Links